Quintiles has reported a strategic alliance agreement with the University of Pretoria as part of its Prime Site program, an initiative to accelerate the development of new and more effective medicines.
Reportedly, the company has been testing 28 different drugs across both the sites in 2009, and shall look to continue to build on these successes at the University of Pretoria site.
Gillian Corken, CEO of Quintiles in Africa, said: “The addition of University of Pretoria to the Prime Site program is a key milestone for Quintiles and also for us in South Africa as it recognizes the quality of our clinical research. Taking some key learnings from both Queen Mary’s College and the Washington Hospital Center, and with the enthusiasm and vision for this unprecedented model that our University of Pretoria partners have shown, we have confidence in being able to accelerate the initiation of this site. By consolidating research in areas of high patient and investigator density we can dramatically improve efficiencies particularly in feasibility and recruitment.”